The evolution of genomic analysis technologies has offered a new paradigm for the business models that utilize them. At the core of such advancement is the development of NGS, or next-generation sequencing. With these technologies, it has become possible to reduce the cost of sequencing down to $1000 per person, which could have the effect of increasing the public’s interest in genomic information and demand for analyses.
We may predict that, in a near future, scientific and medical decisions will be made largely based on the interpretation of the cumulative genomic data. Ultimately, we expect that there will be a shift from ‘treatment’ of diseases to ‘prediction and management,’ thereby improving our overall quality of life.
To download, please enter your information below: